Virios TherapeuticsNASDAQ: VIRI

- Bateman Horne Center completed enrollment in its groundbreaking investigator-initiated Long-COVID phase 2a study featuring valacyclovir and celecoxib (IMC-2) -

- Virios projects releasing top line results from this groundbreaking Proof of Concept study in October 2024 - - Published data indicates increased Epstein-Barr herpes virus in Long-COVID patients, highlighting potential for antiviral therapy to treat fatigue and other Long-COVID symptoms - ATLANTA, July 23, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“FM”) and Long-COVID (“LC”), today announced that the Bateman Horne Center (“BHC”) has completed enrollment in its investigator-initiated, proof of concept LC study. Top line data from this study are projected to be released in October 2024.

ATLANTA, May 22, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company” or “Virios Therapeutics”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“FM”) and Long-COVID (“LC”), today announced the closing of its previously announced public offering of 8,500,000 shares of its common stock at a public offering price of $0.20 per share. Gross proceeds from the offering are $1.7 million before deducting placement agent fees and offering expenses. Virios Therapeutics intends to use the net proceeds of the offering to commence preparatory activities for its planned IMC-2 Long-COVID Phase 2b study and for general corporate purposes.

Virios Therapeutics (NASDAQ: VIRI ) stock is falling on Monday after the development-stage biotechnology company announced the pricing of a public offering for its shares. Virios Therapeutics is selling 8.5 million shares of VIRI stock at a price of 20 cents per share.

Virios Therapeutics, a biotechnology company focusing on developing antiviral therapies for chronic diseases, announced the pricing of its public offering of 8,500,000 shares of common stock at $0.20 per share. The offering is expected to raise approximately $1.7 million before expenses. The company plans to use the proceeds for preparatory activities for its IMC-2 Long-COVID Phase 2b study and for general corporate purposes.

Virios Therapeutics, Inc. announced plans to raise up to $2.1 million through a public offering of its common stock. The funds will be used for preparatory activities for its IMC-2 Long-COVID Phase 2b study and for general corporate purposes. The completion and terms of the offering are subject to market conditions.

Virios Therapeutics, Inc. (Nasdaq: VIRI) will release its first quarter 2024 financial results on May 9, 2024 and hold a webcast and conference call at 8:30 a.m. ET to discuss the results and provide a corporate update. The company focuses on developing innovative antiviral therapies for chronic diseases such as fibromyalgia and Long-COVID.

Virios Therapeutics, Inc. (NASDAQ:VIRI ) Q3 2023 Earnings Conference Call November 13, 2023 8:30 AM ET Company Participants Greg Duncan - CEO Angela Walsh - SVP, Finance & Treasurer Mike Gendreau - CMO Conference Call Participants David Bautz - Zacks Small Cap Research Sean Lee - H.C. Wainwright Operator Good day, and welcome to the Virios Therapeutics, Inc. Third Quarter 2023 Earnings Update.

ATLANTA, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases such as fibromyalgia (“FM”) and Long-COVID (“LC”), announced today that Greg Duncan, Chairman and Chief Executive Officer, will present at the SHARE™️ Series Monday Management Update for investors on Monday, September 18, 2023, at 11:00 am ET.